|
|
|
|
|
|
|
|
thalidomide and lenalidomide
$39.95 / €34.95 / £29.95 *
Thalidomide and lenalidomide are structural analogs and immunomodulatory drugs.
Lenalidomide appears to have a different safety profile than thalidomide
and could be less toxic, and as far as we know, we did not found any
study comparing their safety profile. The objective of our study was to
review and compare serious adverse drug reactions (SADRs) of thalidomide
and lenalidomide spontaneously reported to the French Pharmacovigilance
database. We extracted all medically confirmed spontaneous reports of
SADR for lenalidomide-based regimens and thalidomide-based regimens from
the French Pharmacovigilance database. A “serious” adverse drug
reaction (ADR) was defined as an ADR that is fatal or life threatening,
which causes hospitalization or prolongation of hospitalization, or
permanent or significant disability. The study period was between
marketing of 2 drugs and January 15, 2012. A total of 392 SADRs related
to thalidomide-based regimens were identified in 244 patients and 377
SADRs related to lenalidomide-based regimens in 220 patients. In spite
of their structural analogy, this study highlights interesting
differences between lenalidomide and thalidomide’s safety profile:
nervous system and vascular disorders are more frequent with
thalidomide-based regimens while hematologic, skin, infectious disorders
and secondary primary cancers are more frequent with lenalidomide-based
regimens.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.